» Articles » PMID: 33850637

Seed-mediated RNA Interference of Androgen Signaling and Survival Networks Induces Cell Death in Prostate Cancer Cells

Overview
Publisher Cell Press
Date 2021 Apr 14
PMID 33850637
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to anti-androgen therapy in prostate cancer (PCa) is often driven by genetic and epigenetic aberrations in the androgen receptor (AR) and coregulators that maintain androgen signaling activity. We show that specific small RNAs downregulate expression of multiple essential and androgen receptor-coregulatory genes, leading to potent androgen signaling inhibition and PCa cell death. Expression of different short hairpin/small interfering RNAs (sh-/siRNAs) designed to target preferentially reduce viability of PCa but not benign cells, and growth of murine xenografts. Surprisingly, this effect is independent of expression. Transcriptomic and sh/siRNA seed sequence studies indicate that expression of these toxic shRNAs lead to downregulation of androgen receptor-coregulatory and essential genes through mRNA 3' UTR sequence complementarity to the seed sequence of the toxic shRNAs. These findings reveal a form of the "death induced by survival gene elimination" mechanism in PCa cells that mainly targets AR signaling, and that we have termed androgen network death induced by survival gene elimination (AN-DISE). Our data suggest that AN-DISE may be a novel therapeutic strategy for PCa.

Citing Articles

Identification of ferroptosis related genes and pathways in prostate cancer cells under erastin exposure.

Wu F, Huang F, Jiang N, Su J, Yao S, Liang B BMC Urol. 2024; 24(1):78.

PMID: 38575966 PMC: 10996193. DOI: 10.1186/s12894-024-01472-1.


Cancer kill code extension.

Peter M Mol Ther Nucleic Acids. 2023; 33:773.

PMID: 37655044 PMC: 10466420. DOI: 10.1016/j.omtn.2023.08.003.


An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth.

Corbin J, Georgescu C, Wang L, Wren J, Bieniasz M, Xu C Mol Ther Nucleic Acids. 2023; 33:257-272.

PMID: 37554515 PMC: 10404560. DOI: 10.1016/j.omtn.2023.06.021.


Identification of the toxic 6mer seed consensus for human cancer cells.

Patel M, Bartom E, Paudel B, Kocherginsky M, OShea K, Murmann A Sci Rep. 2022; 12(1):5130.

PMID: 35332222 PMC: 8948288. DOI: 10.1038/s41598-022-09051-w.


DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases.

Haluck-Kangas A, Patel M, Paudel B, Vaidyanathan A, Murmann A, Peter M J Exp Clin Cancer Res. 2021; 40(1):389.

PMID: 34893072 PMC: 8662895. DOI: 10.1186/s13046-021-02177-1.


References
1.
Davey R, Grossmann M . Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016; 37(1):3-15. PMC: 4810760. View

2.
Fujiwara N, Inoue J, Kawano T, Tanimoto K, Kozaki K, Inazawa J . miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity. Cancer Res. 2015; 75(18):3890-901. DOI: 10.1158/0008-5472.CAN-15-0257. View

3.
Xie Q, Liu Y, Cai T, Horton C, Stefanson J, Wang Z . Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun. 2017; 8:14284. PMC: 5264212. DOI: 10.1038/ncomms14284. View

4.
Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O . First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014; 32(36):4141-8. DOI: 10.1200/JCO.2013.55.0376. View

5.
Xu K, Wu Z, Groner A, He H, Cai C, Lis R . EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338(6113):1465-9. PMC: 3625962. DOI: 10.1126/science.1227604. View